iron infusion

If I pushed through the pain of the iron pills for a month or so, I’d get my level up to the 10 and 11 range where everybody seemed satisfied but only months later, I’d start feeling the effects of anemia and it was starting to affect my heart.
Are you struggling with Iron Deficiency Anemia? Are you going to start infusion therapy or have you been through it already.
I will tell you that I’ve struggled with my anemia since that time and with each and every doctor, one of the first things they say is, "Did you know you’re anemic?" Normal hemoglobin levels for women are between 12 to 18.
Hey, I’ve had lower levels but, given my history, she felt iron infusion therapy would help.
Three years ago, I had a physician who had run the gamut of tests and was sending me to a Hematologist to investigate iron infusion therapy.
Once the results of the blood test were brought in, she promptly announced that I needed an iron infusion first and foremost.
I have been suffering from Iron Deficiency Anemia now for the better part of ten years.
Not only had my iron levels gone from non existent but she said they were excellent now! Let me just say, I was so thrilled that I would have gladly named my daughter after this doctor in apprecation.
I joked with my family about feeling like actual iron had been pumped into my body because my legs felt leaden just walking around the house.
In a nutshell, iron infusion therapy is iron being delivered into your body intravenously.

FIRST: head-to-head comparison study (Ferumoxytol compared to IRon Sucrose Trial) of the safety and efficacy of ferumoxytol with iron sucrose for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD).
TREATMENT OF FATIGUE IN NONANEMIC SUBJECTS — A randomized, double-blind study evaluated the efficacy and safety of intravenous iron (cumulative dose: 800 mg of iron as iron (III)-hydroxide sucrose given in four infusions over a two-week period) versus placebo (0.9 percent saline) for the treatment of fatigue in 90 nonanemic (hemoglobin ≥12.0 g/dL) premenopausal women with serum ferritin levels ≤50 ng/mL.
●Because of ease of treatment, we recommend that patients with uncomplicated iron deficiency anemia be treated with oral iron rather than an intravenous (IV) iron formulation (Grade 1B).
A second randomized trial compared ferumoxytol with iron sucrose for the treatment of iron deficiency anemia in 605 adult patients with a history of unsatisfactory oral iron therapy or intolerance to oral iron.
Efficacy and tolerability of intravenous ferric gluconate in the treatment of iron deficiency anemia in patients without kidney disease.
A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy.
This agent is licensed for use in Europe, Asia, and New Zealand, and is approved for use in the United States in patients with iron deficiency anemia and intolerance or unsatisfactory response to oral iron and for treatment of iron deficiency anemia in adults with nondialysis-dependent chronic kidney disease.
Results are available from a randomized, double-blind safety and efficacy trial of intravenous ferumoxytol (n = 609, 510 mg administered in under one minute and repeated two to eight days later) versus intravenous placebo (n = 203, administered in the same fashion) in adults with iron deficiency anemia previously unresponsive to, or unable to tolerate, oral iron.
FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.
A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
One group has reported on the efficacy and safety of 125 mg of ferric gluconate complex given either undiluted by slow IV push at a rate of 12.5 mg/minute or diluted in 100 mL isotonic saline and infused over 30 to 60 minutes, in 74 patients with iron deficiency anemia and normal levels of serum creatinine [47].
●When the risk of infection was specifically determined in large trials in hemodialysis patients [83], patients with iron deficiency anemia plus non-dialysis-dependent chronic kidney disease [63], those with heart failure [60], following cardiac [84] or orthopedic surgery [85], or in those with chemotherapy-induced anemia [86,87], the use of IV iron was not associated with an increased risk of infection.
The US Food and Drug Administration (FDA) has approved ferumoxytol for the treatment of iron deficiency anemia in adult patients with chronic kidney disease.
There exist only a small number of randomized, prospective trials comparing the relative safety of the various intravenous iron preparations [73]: three have shown relatively equal safety for low molecular weight iron dextran and iron sucrose [70,74,75]; one has shown relatively equal safety for iron sucrose and ferric gluconate complex [76]; while one, in abstract form, has shown comparability of safety between iron sucrose and ferumoxytol [77].
A number of trials have shown efficacy and safety of this agent in iron deficient patients in a number of different settings (eg, heavy uterine bleeding, postpartum women, chronic renal failure, inflammatory bowel disease, heart failure, nonresponse to oral iron) [10,57-63].
Inflammatory bowel disease — Many patients with inflammatory bowel disease (IBD) and iron deficiency have severe intolerance to oral iron preparations, which may also worsen IBD disease activity.
Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation.
Chronic kidney disease — IV iron is the current standard in both dialysis and non-dialysis associated chronic kidney disease patients for multiple reasons, including ongoing blood loss associated with the procedure, the need for adequate iron to respond to the administration of erythropoietic stimulating agents, as well as the frequent inability of these patients to utilize iron administered orally [5,6].
An observational study in anemic cancer patients receiving IV iron (ferric carboxymaltose, median dose 1000 mg of elemental iron) indicated that patients with baseline hemoglobin levels up to 11.0 g/dL and serum ferritin levels up to 500 ng/mL responded to treatment with an increase in hemoglobin and a reduction in the need for red cell transfusions [39].
Numerous studies in the United States and other countries have demonstrated the safety and efficacy of iron sucrose, LMW iron dextran, ferumoxytol, and ferric carboxymaltose in patients with inflammatory bowel disease [4,34,35].
However, in that there is no evidence that doses larger than 1000 mg are clinically useful, it has been our policy to routinely administer a fixed 1000 mg dose over one hour to iron deficient patients receiving intravenous low molecular weight iron dextran [27].
●The patient has an inherited condition associated with iron deficiency anemia and a failure to respond to treatment with oral iron (eg, iron-resistant iron deficiency anemia, IRIDA).
The efficacy and safety of ferumoxytol are further supported by a prospective, randomized study in 162 patients with chronic kidney disease (CKD) randomly assigned to receive either 1.02 grams of ferumoxytol administered as two 510 mg injections (administered by rapid IV bolus injection) or 10 IV doses of 100 mg of iron sucrose in those with CKD undergoing dialysis or 200 mg of IV iron sucrose in non-dialysis CKD.
Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia.
●Some physicians stop treatment with iron when the hemoglobin level becomes normal, so that further blood loss will cause anemia and alert the patient and physician to the return of the problem which caused the iron deficiency in the first place.
It has been deemed safe and effective when given as a rapid intravenous infusion of up to 510 mg of elemental iron in a volume of 17 mL (infusion rate: up to 1 mL/second) in patients with chronic kidney disease (CKD) and those on dialysis [51].
Test dose — Product labeling for ferric gluconate does not indicate the need for a test dose, however in patients with a sensitivity to iron dextran or with other drug allergies a test dose is recommended.
●For patients who have a history of intolerance to oral iron therapy, published evidence supports a larger and earlier role for intravenous iron.
Test dose — Product labeling for iron sucrose does not indicate the need for a test dose in product-naive patients, but a test dose is recommended (25 mg by slow IV push) in patients who are sensitive to iron dextran or have other drug allergies.
BLOOD TRANSFUSION — For the patient who is hemodynamically unstable because of active bleeding, and/or who shows evidence for end-organ ischemia secondary to severe iron deficiency anemia, packed red blood cell transfusion can be life saving.
Ferric carboxymaltose — Ferric carboxymaltose (Ferinject, Injectafer) is a novel stable iron complex for intravenous use that can be given at single doses of up to 1000 mg of elemental iron per week over a recommended infusion time of 15 minutes.
The uses of iron preparations for the treatment of functional iron deficiency in patients with chronic kidney disease as well as malignancy being treated with erythropoietin are specialized subjects and are presented separately.
Non-response to oral iron therapy does not rule out iron deficiency in such subjects, since two-thirds of the non-responders to oral iron in one study responded to treatment with intravenous iron (ferric carboxymaltose) [10].
As a result, intravenous iron is considered frontline therapy in Europe for iron deficiency anemia associated with IBD with or without oral iron intolerance or ineffectiveness [4].
Failure of response to oral iron therapy in these settings does not rule out the presence of iron deficiency, as some will respond to treatment with intravenous iron.
Use in cancer patients — A large number of prospective studies support the observation that IV iron, unlike oral iron, synergizes with erythropoiesis-stimulating agents (eg, erythropoietin, darbepoetin) therapy in anemic cancer patients both on and off chemotherapy [9].
●In a series of 1266 infusions of low molecular weight iron dextran (1 gram infused over one hour) given to 888 patients, 162 of whom were pregnant, no severe adverse events were noted [31].
●The proportion of patients achieving a hemoglobin increase of ≥2 g/dL at any time between baseline and five weeks, the primary efficacy endpoint, was 84 versus 81 percent for those receiving ferumoxytol or iron sucrose, respectively.
Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy.
A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.
•Oral iron, unlike the intravenous preparations, does not synergize well with ESAs (eg, erythropoietin, darbepoetin) in anemic cancer patients both on and off chemotherapy [8,9].
Side effects — Estimates are that up to 50 percent of patients complain of nausea, constipation, diarrhea, epigastric distress and/or vomiting after taking various oral iron preparations [17].
A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED).
Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial.
While the preponderance of published evidence indicates that low molecular iron dextran preparations are associated with fewer adverse reactions than high molecular weight iron dextran preparations [78], it is not otherwise possible at this time to conclude that any one intravenous iron preparation is safer than another [33,69].
In one study, for example, refractoriness to oral iron treatment was noted in all patients with celiac disease and approximately 70 percent of those with autoimmune atrophic gastritis or Helicobacter pylori infection [19].
Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia.
Diagnostic issues — Successful overall management of the patient with iron deficiency anemia requires an attempt to identify and treat the underlying cause(s) of the iron deficiency (eg, blood loss from a tumor, varicosity, or other bleeding lesion; iron malabsorption).
Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial.
•It has been estimated that the maximum amount of elemental iron that can be absorbed with an oral iron preparation is 25 mg/day [11], whereas, depending upon the preparation used, up to 1000 mg of elemental iron can be administered following a single infusion of intravenous iron.
Intravenous versus oral iron for treatment of anemia in pregnancy: a randomized trial.
Iron therapy in iron deficiency anemia in pregnancy: intravenous route versus oral route.
Treatment issues — The choice of iron preparation depends upon the acuity of illness, as well as the ability of the patient to tolerate oral iron preparations.
Prevention and treatment of adverse drug events — The following sections should be required reading for all clinicians contemplating the use of an intravenous iron preparation.
Iron sucrose has been shown to be safe and efficacious in dialysis, non-dialysis CKD, inflammatory bowel disease, chemotherapy-induced anemia, the peripartum period, gastric bypass, heavy uterine bleeding, and a host of other conditions associated with iron lack.
●For patients who have failed to respond to oral or parenteral iron therapy, the cause for this failure should be determined and appropriate action undertaken.
Indications for treatment — While some patients with iron deficiency anemia will be asymptomatic, most will have symptoms.
Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron.
Iron dextran — Iron dextran preparations contain 50 mg of elemental iron/mL, and can be given either by the intramuscular (IM) or intravenous (IV) route.
A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.
•In patients with inflammatory bowel disease, the use of oral iron has been associated with worsening of the underlying disease, and may be poorly tolerated and ineffective [4].
Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia.
Given the safety and efficacy of IV iron in a broad spectrum of diseases associated with iron deficiency, the current paradigm that oral iron is first line therapy should be reconsidered [33].
A prospective randomized, controlled trial of intravenous versus oral iron for moderate iron deficiency anaemia of pregnancy.
For patients with chemotherapy induced anemia, NCCN Guidelines state that intravenous iron is the preferred route when iron supplementation is indicated, and K/DOQI guidelines indicate its use for iron replacement in dialysis patients.
•Non-dialysis chronic kidney disease patients have a number of reasons for their inability to absorb oral iron (eg, impaired iron transport, concomitant use of calcium-containing salts, H2 blockers, phosphate binders, generalized malabsorption) [7].
In a randomized study in 90 iron deficient hospitalized patients >80 years of age, daily doses of 15, 50, or 150 mg of elemental iron for two months were equally effective in raising hemoglobin and ferritin concentrations, while adverse side effects were significantly more common at the higher iron doses [16].
Correction of anemia — Assume, for example, that a 60 kg woman with a hemoglobin concentration of 8 g/dL due to iron deficiency needs parenteral iron replacement, which will be given intravenously in the form of iron sucrose (20 mg iron/mL).
●Patients with persistent gastric intolerance to oral iron tablets may tolerate ferrous sulfate elixir, which provides 44 mg of elemental iron per 5 mL.
Excessive continuing blood loss — Currently, parenteral iron is most often used in iron deficient patients whose level of continued bleeding, usually gastrointestinal or menstrual, exceeds the ability of the gastrointestinal tract to absorb iron.
The recommended oral daily dose for the treatment of iron deficiency in adults is in the range of 150 to 200 mg/day of elemental iron.
However, other studies have shown that iron given orally can also improve fatigue in similar patients [94-97], can improve exercise capacity in nonanemic adolescent runners with serum ferritin levels <20 ng/mL [98], and can improve symptoms of fatigue in nonanemic female blood donors with serum ferritins <10 ng/mL [99].
●Treatment with intravenous iron significantly increased serum ferritin levels and transferrin saturation, but did not increase hemoglobin values.
•Intravenous iron is required when the amount of iron lost through daily blood loss exceeds the capacity of the gastrointestinal tract to absorb oral iron preparations.
Data from Europe and the United States indicate that, compared with iron dextran, sodium ferric gluconate complex in sucrose has a reduced incidence of adverse allergic reactions (3.3 versus 8.7 allergic events per one million doses per year) [45].
A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients.
However, while we have seen such anaphylactic-type reactions to high molecular weight iron dextran, we have not seen such reactions after infusions of low molecular weight iron dextran preparations [68], ferumoxytol, iron sucrose, or ferric gluconate complex.
General principles — Oral iron provides an inexpensive and effective means of restoring iron balance in a patient with iron deficiency without complicating co-morbid conditions.
●In our practice, we routinely administer 1000 mg of low molecular weight iron dextran in one hour to iron deficient pregnant women whether or not they are oral iron intolerant [27].
A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo.
However, with the advent of parenteral iron formulations with more favorable toxicity profiles, the early use of intravenous iron should be considered in those intolerant to the use of oral iron preparations (see ‘Parenteral iron therapy’ below).
Unlike LMW iron dextran, ferumoxytol, ferric carboxymaltose, and iron isomaltoside, iron sucrose cannot be administered as a total dose infusion and doses above 300 mg are not recommended [50].
While numerous publications have shown the safety and efficacy of parenteral iron in this setting [21-30], its use in pregnancy is sporadic at best and is hindered by the fact that no parenteral iron preparation has been given a US Food and Drug Administration (FDA) category "A" rating for use in pregnancy (ie, controlled human studies show no risk) (table 3).
●Parenteral iron – Clinicians’ historical reluctance to use parenteral iron preparations more widely can be traced, at least in part, to severe side effects (eg, anaphylaxis, shock, death) associated with earlier parenteral iron preparations, such as high molecular weight iron dextran.
TDI of LMW iron dextran has been shown to be safe and effective in pregnancy, the peripartum period, heavy uterine bleeding, inflammatory bowel disease, gastric bypass, hereditary hemorrhagic telangiectasias, chronic kidney disease, and the restless legs syndrome [27,43,44].
●Patients with severe malabsorption and/or malnutrition may not be candidates for IM treatment if they have a markedly reduced muscle mass into which the iron preparation can be injected.
A test dose of a 20 mg injection or 25 mg infusion of iron sucrose was given to iron sucrose-naïve patients in compliance with labeling requirements of the countries in which this study was conducted.
●If pagophagia (pica for ice) or restless leg syndrome is present, it often disappears almost as soon as oral or intravenous iron therapy is begun, well before there are any observable hematologic changes such as reticulocyte response.
Given the preponderance of published evidence on the safety of intravenous iron in the pregnant patient, we believe that the failure to use intravenous iron in this population appears to represent an unmet clinical need.
•Clinicians contemplating the use of intravenous iron preparations should be fully conversant with requirements for a test dose, rates of infusion, maximum allowed doses, and the need, if any, for premedication.
Public health aspects — More than a quarter of the world’s population is anemic, and about one-half of this burden is a result of iron deficiency anemia, being most prevalent among preschool children and women [1].
INTRODUCTION — The management of adults with anemia due to iron deficiency, including the relevant diagnostic and therapeutic issues as well as the choice of iron preparation, will be discussed here.
Repletion of iron stores — The issue of whether to replete iron stores in the patient with iron deficiency anemia is discussed above.
Risk of infection — Bacteria and other infectious agents require iron as a growth factor, and patients with hereditary hemochromatosis and iron overload are known to be at increased risk for certain serious bacterial infections [80].
In addition, they could not uncover a dose-response association between iron and infectious risk, and rates of mortality and other serious events in patients randomly assigned to treatment with IV iron were not increased [81,82].
Such side effects can be exacerbated by treatment with oral iron, and can be partially managed by reducing the amount of iron given and/or modifying the patient’s diet, both of which require patient adherence.
There is limited information on the efficacy of IV iron in anemic cancer patients receiving chemotherapy in the absence of treatment with erythropoiesis-stimulating agents [9,37,38].
Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy.
Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous? Curr Med Res Opin 2010; 26:473.
•With the advent of parenteral iron formulations with improved toxicity profiles, the early switch to intravenous iron should be considered in those intolerant to the use of oral iron preparations.
The safety of intravenous iron dextran in hemodialysis patients.
Based on the preponderance of published evidence, ferric carboxymaltose is safe and effective, with a side effect profile similar to the other available intravenous iron formulations.
Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials.
•Treatment with oral iron may take as long as six to eight weeks in order to fully ameliorate the anemia, and as long as six months in order to replete iron stores.
Pregnancy — Standard treatment of iron deficiency in pregnancy is the same as that in nonpregnant, postpartum, premenopausal, and postmenopausal women.
Adverse events associated with intravenous iron infusion (low-molecular-weight iron dextran and iron sucrose): a systematic review.
Need for premedication — The reluctance to use intravenous iron is at least in part due to misunderstanding and misinterpretation of the clinical nature of adverse events with IV iron [89].
●Significant improvement in the fatigue score at six weeks, as evaluated by the Brief Fatigue Inventory questionnaire, was noted only in the subgroup of women with serum ferritins ≤15 ng/mL (82 percent with intravenous iron versus 47 percent of those treated with placebo).
Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy.
Otherwise, there is insufficient evidence for the superiority of one parenteral iron preparation over another (ie, iron sucrose, ferric gluconate complex, low molecular weight iron dextran, ferumoxytol) (table 4).
Failure to respond to oral iron therapy — On occasion, a patient may not respond to oral iron therapy.
Adverse events associated with intravenous iron infusion (low-molecular-weight iron dextran and iron sucrose).
Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia? Adv Chronic Kidney Dis 2009; 16:143.
•In conditions such as heavy uterine bleeding, hereditary hemorrhagic telangiectasia, gastric bypass, or other causes of heavy blood loss, absorption of oral iron, even in maximal doses, may be unable to keep up with blood loss.
●A meta-analysis of this subject, which reported an increased risk of infection following the use of IV iron (when compared with oral iron, RR 1.33; 95% CI 1.10-1.64), acknowledged that information on the risk of infection was available in only 24 of the 72 studies included in their meta-analysis, suggesting that missing data could have created unmeasured bias and a false positive result.
For all of the above reasons, including the fact that IM administration of iron dextran has not been shown to be safer or less toxic than the intravenous (IV) route, the most appropriate parenteral route is the IV one [68].
Ferric carboxymaltose in patients with heart failure and iron deficiency.
●Patients who have very brisk continuing bleeding (as with gastrointestinal angiodysplasia) are difficult to treat with an IM regimen because repeated courses of IM iron are painful, and the utilization of iron given via this route is variable.

Talk to health experts and other people like you in WebMD’s Communities.
It’s a safe forum where you can create or participate in support groups and discussions about health topics that interest you.
Protect yourself and your family by learning which health precautions and vaccines are advised for your destination.
WebMD cuts through the hype to reveal the best kept secrets for healthy hair.
Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.
Read expert perspectives on popular health topics.
Got a health question? Get answers provided by leading organizations, doctors, and experts.
WebMD does not provide medical advice, diagnosis or treatment.

Common side effects include muscle cramps, nausea, vomiting, strange taste in the mouth, diarrhea, constipation, headache, cough, back pain, joint pain, dizziness, swelling of the arms/legs, or pain, swelling, or redness at the injection site.
In a randomized, open-label, dose-ranging trial for iron maintenance treatment with Venofer in pediatric patients with CKD on stable erythropoietin therapy [see Clinical Studies], at least one treatment-emergent adverse reaction was experienced by 57% (27/47) of the patients receiving Venofer 0.5 mg/kg, 53% (25/47) of the patients receiving Venofer 1.0 mg/kg, and 55% (26/47) of the patients receiving Venofer 2.0 mg/kg.
Tell your doctor right away if you have any serious side effects, including: abdominal pain, chest pain, irregular heartbeat (arrhythmias), pressure in the chest, severe headache and blurred vision (hypertension), problems with your dialysis access site (graft).
Our Venofer (iron sucrose) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
Treatment-emergent adverse reactions reported by ≥ 2% of treated patients in the six clinical trials for which the rate for Venofer exceeds the rate for comparator are listed by indication in Table 1.
The frequency of adverse reactions associated with the use of Venofer has been documented in six clinical trials involving 231 patients with HDD-CKD, 139 patients with NDD-CKD and 75 patients with PDD-CKD.
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: Anaphylactic-type reactions, shock, loss of consciousness, collapse, bronchospasm, dyspnea, convulsions, lightheadedness, confusion, angioedema, swelling of the joints, hyperhidrosis, back pain, bradycardia, and chromaturia.
A total of 5 (11%) subjects in the Venofer 0.5 mg/kg group, 10 (21%) patients in the Venofer 1.0 mg/kg group, and 10 (21%) patients in the Venofer 2.0 mg/kg group experienced at least 1 serious adverse reaction during the study.
Symptoms associated with Venofer total dosage or infusing too rapidly included hypotension, dyspnea, headache, vomiting, nausea, dizziness, joint aches, paresthesia, abdominal and muscle pain, edema, and cardiovascular collapse.
SIDE EFFECTS: Muscle cramps, nausea, vomiting, strange taste in the mouth, diarrhea, constipation, headache, cough, back pain, joint pain, dizziness, or swelling of the arms/legs may occur.

A safe and much more rapid method of replenishing the patient’s iron stores is to admit them to the Centre for Digestive Diseases for several hours, infuse a large number of ampoules of iron through the vein “as a drip”, and so help the bone marrow to have enough iron available fairly quickly to make new red cells and to restore the person’s blood concentration.

The Intravenous (IV) Iron Infusions Patient Information leaflet available on the BloodSafe (Department of Health, South Australia) website provides practical information and answers some common questions about IV iron infusions.
Factsheet developed by Fremantle Hospital answering some common questions about IV iron infusions and is available on Government of Western Australia Patient Blood Management website.
Due to varied practice and little evidence currently available around  iron infusion it is important to seek pharmacy and hospital policy committee approval regarding introduction of policy into your own hospital setting.
Studies are currently being performed on iron rapid iron infusion/bolus, other hospitals in Melbourne have changed practice and using iron carboxymaltose only to treat iron deficiency anaemia parentally.
We have gathered articles, product information, links to resources and have developed guiding principles to assist you in developing your own iron infusion policy/procedure.

Local side effects have included injection site pain, inflammation and swelling, cellulitis, phlebitis, sterile abscess, brown skin staining at injection site (harmless), sarcoma formation, and necrosis.
Hepatic side effects have included hemosiderosis, the accumulation of unusable iron in the liver and spleen.
Hypersensitivity side effects have included dyspnea, urticaria, rashes, itching, arthralgia, myalgia, fever, and sweating.
Delayed reactions may occur 1 to 2 days after administration of iron dextran, manifested by arthralgia, backache, myalgia, fever, chills, dizziness, headache, nausea and/or vomiting.
Cardiovascular side effects have included chest pain or tightness, shock, hypotension, hypertension, tachycardia, flushing, and arrhythmias.
Musculoskeletal side effects have included arthralgia, arthritis (possible reactivation of quiescent rheumatoid arthritis), myalgia, and backache.
Not all side effects for iron dextran may be reported.
Nervous system side effects have included headache, transient paresthesia, weakness, dizziness, syncope, disorientation, unresponsiveness and seizures.
General side effects have rarely included severe adverse reactions (less than 5%).
Immunologic side effects have included a possible increase in susceptibility to infections.
Hematologic side effects have included leukocytosis, lymphadenopathy, latent folic acid deficiency, pleocytosis, pancytopenia, thrombocytopenia, and purpura.
Gastrointestinal side effects have included abdominal pain, nausea, vomiting, and diarrhea.
Ocular side effects have rarely included pigment epitheliopathy with serious detachment of the retina (one case report).
When dextrose 5% is used as a diluent in total dose infusion of iron dextran, a higher incidence of phlebitis and local injection pain has been seen.
Respiratory side effects have included dyspnea, bronchospasm and respiratory arrest.
These effects have especially been observed with intramuscular injections of iron dextran.
The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects.
Oncologic side effects have included reports of sarcoma.

The goals of treating iron-deficiency anemia are to treat its underlying cause and restore normal levels of red blood cells, hemoglobin, and iron.
Severe iron-deficiency anemia may require a blood transfusion, iron injections, or intravenous (IV) iron therapy.

However, if clinical circumstances require rapid delivery of iron to the body iron stores CosmoFer® may be administered as a total dose infusion up to a total replacement dose corresponding to 20 mg iron/kg body weight.  The CosmoFer® injection should not be administered concomitantly with oral iron preparations as the absorption of oral iron will be reduced.
CosmoFer® may be administered in a dose of 100 – 200 mg iron (2-4 ml) by slow intravenous injection (0.2 ml/min) preferably diluted in 10 – 20 ml 0.9% sodium chloride or 5% glucose solution.
The dose and dosage schedule for CosmoFer® must be individually estimated for each patient based on a calculation of the total iron deficit.

Medscape uses cookies to customize the site based on the information we collect at registration.
The cookies contain no personally identifiable information and have no effect once you leave the Medscape site.
In order to use Medscape, your browser must be set to accept cookies delivered by the Medscape site.

Signs and symptoms of iron overload include tiredness, irregular heartbeat and heart failure, joint pain, loss of fertility, erectile dysfunction and change in skin color.
Administration of iron dextran appears to have a higher rate of anaphylaxis compared to other intravenous iron products, according to the report authors.
Low blood pressure is the most common side effect associated with injection of iron sucrose and iron gluconate.
Newer Food and Drug Administration-approved iron preparations include ferric carboxymaltose, another sugar complex, and ferumoxytol, an iron carbohydrate complex.
People with chronic kidney disease are most commonly given IVI, although this treatment may be recommended for people with another condition that reduces iron absorption from the intestines.

Patients who are most often given these drugs to stimulate the production of red blood cells are those who have anemia caused by cancer chemotherapy treatment, kidney failure, drugs used to treat AIDS, or those who are scheduled to have surgery.4 Some elderly patients or patients with inflammatory bowel disease or rheumatoid arthritis may also benefit from iron injections and ESA treatment.5-7 Read more about ESAs in ESA Drugs Treat Anemia By Stimulating Red Blood Cell Production.
Iron injections are generally given to patients with a severe iron deficiency to make sure their body has enough iron to make healthy red blood cells.
In the United States, the most common cause of anemia is iron deficiency, which means the body does not have enough iron.1 Treatments for this shortage of iron can include eating a healthy diet, taking iron pills and possibly receiving iron injections.
To find out if iron injections can help you feel better, talk with your doctor about your symptoms, medical history and any current treatments you are receiving for iron deficiency or anemia.
They may also be given to patients who have extremely low levels of iron or who have lost a large amount of blood.3 Because iron by injection does not have to be absorbed through the intestines, but is delivered directly to your circulatory system, it can help build red blood cells more quickly than oral iron.
Patients receiving iron injections can experience side effects, including flushing, headache, muscle and joint pain, dizziness, nausea, rashes, pain and inflammation at the injection site, fever or chills.
Close communication with your doctor about your symptoms, medical history and side effects will help him or her provide the necessary treatments for iron deficiency and anemia.
Iron injections are often given because patients are not able to take their full dose of oral iron or their body cannot properly absorb iron through their digestive tract.
Reporting side effects is very important to help your doctor make sure iron injections are safely and effectively treating your iron deficiency.
Correctly diagnosing and treating an iron deficiency is an important step to feeling better, so it is essential that you discuss your symptoms with a doctor or medical professional to find out if iron injections are right for you.
To prepare you for a discussion with your doctor, this article includes information about iron injections and treating iron deficiency and anemia.
The body can make red blood cells, even when it has an iron deficiency, but eventually the shortage of stored iron can slow that process and cause anemia.
For anemic patients receiving drugs called erythropoiesis-stimulating agents (ESAs), iron injections are necessary to ensure that the body has an ample and steady supply of iron.
Iron deficiency anemia is a condition that develops when a low iron level persists and prevents the body from making enough healthy red blood cells.
Once you have started treatment, your doctor will need to closely monitor how your body reacts to the iron injections.
If you receive an iron injection, be sure to immediately report any of these or other side effects to your doctor or healthcare professional.
Iron injections can be a helpful treatment for iron deficiency and anemia, but it may take a while for them to reach their full effect.
For your safety and comfort, your doctor will also monitor any side effects you may experience as a result of the iron injections.

Patients diagnosed with severe iron deficiency may require iron infusion therapy, which involves intravenous delivery of iron products.
Hemoglobin levels average 11 to 13 grams per deciliter of blood and indicate the amount of iron protein in red blood cells that carries oxygen throughout the body.
End stage renal disease is one of the more common reasons for patients to require iron infusion therapy.
I imagine getting an iron infusion would be somewhat similar, seeing as it’s basically the same kind of substance going into your blood stream.
Often I don’t even realize how bad I’ve been feeling until after I have the supplement and start to feel better, so I can’t even imagine how poorly people who need an infusion of iron must feel before they get the iron they need.
Allergic reactions are a primary concern in patients receiving iron infusion therapy.
Chemotherapy, chronic inflammatory bowel diseases, and kidney failure are some of the conditions that might require iron replacement by infusion.
Iron infusion therapy may help some patients with ulcerative colitis.
@pleonasm – It sounds like most of the reasons that people might need this kind of infusion are pretty serious, so unfortunately, I think they might be feeling pretty bad anyway, iron or no iron.
Iron deficiency occurs when the body cannot produce enough red blood cells to compensate for a loss.
Iron infusion treatments may take anywhere from three to eight hours, depending on the degree of anemia and the prescribed dosage.
Iron infusion therapy is done intravenously to treat severe iron deficiencies.
Iron levels within blood average between 40 to 150 micrograms per deciliter in women and 50 to 160 micrograms per deciliter for men.
Common side effects of iron infusion include dizziness, flushing, headache, and a metallic taste in the mouth.
Individuals typically receive iron infusion therapy in a hospital setting.
Ferric gluconate, iron dextran, and iron sucrose complexes, diluted in normal saline, are some of the products used for infusion.
Prior to beginning the treatment, technicians usually administer a testing dose of around 25 milligrams of iron intravenously while monitoring vital signs and checking for symptoms of adverse reactions.

The cumulative iron dose required may be administered in a single Monofer infusion up to 20 mg iron/kg body weight or as weekly infusions until the cumulative iron dose has been administered.
After the current iron deficit has been corrected, patients may require continued therapy with Monofer to maintain target levels of haemoglobin and acceptable limits of other iron parameters.
The iron is available in a non-ionic water-soluble form in an aqueous solution with pH between 5.0 and 7.0. The toxicity is low and Monofer can therefore be administered in large doses.
There is also an increased risk of hypersensitivity reactions to parenteral iron complexes in patients with immune or inflammatory conditions (e.g. systemic lupus erythematosus, rheumatoid arthritis).
Due to limited clinical data on Monofer the mentioned undesirable effects are primarily based on safety data for other parenteral iron solutions.
Large doses of parenteral iron (5 ml or more) have been reported to give a brown colour to serum from a blood sample drawn four hours after administration.
Hypersensitivity reactions have also been reported after previously uneventful doses of parenteral iron complexes.
Oral iron therapy should not be started earlier than 5 days after the last injection of Monofer.
Monofer solution for injection is a colloid with strongly bound iron in spheroidal iron-carbohydrate particles.
Parenterally administered iron preparations can cause hypersensitivity reactions including serious and potentially fatal anaphylactic/anaphylactoid reactions.
The Monofer formulation contains iron in a strongly bound complex that enables a controlled and slow release of bioavailable iron to iron-binding proteins with little risk of free iron.
Acute, severe anaphylactoid reactions may occur with parenteral iron preparations, although they are uncommon.
Iron complexes have been reported to be teratogenic and embryocidal in non-anaemic pregnant animals at high single doses above 125 mg iron/kg body weight.

An average total-dose infusion of iron polymaltose (sufficient to replenish iron stores, commonly 1000 mg–2500 mg for adults), given at the rates recommended in Australian approved product information, takes around 5 hours.
Consultation with these health services regarding the implementation of the National Blood Authority’s Patient Blood Management work plan, in particular the management of anaemia, identified a gap in publically available resources relating to iron infusion management, which has lead to the development of these guiding principles.
*average total-dose infusion of iron polymaltose (sufficient to replenish iron stores, commonly 1000 mg–2500 mg for adults).
Iron polymaltose has been identified as well tolerated with minor infrequent side effects during infusion and some self limiting side effects that occur up to 2 days after infusion.
A “total-dose” infusion (where iron stores can be repleted in a single treatment episode) can be administered only with iron polymaltose.

Hey girlfriends (and guy friends too), Ronnetta Griffin of Iron Disorders Institute invites you to come along for a behind-the-scenes look at IV Iron Infusions! In "The Girlfriends' Guide to Iron Infusions," Ronnetta takes you through her own personal experience over the course of six days for four IV Iron Infusions to treat her Iron Deficiency Anemia (IDA).

It does seem more than plausible that this patient’s eosinophilic fasciitis is related to the intravenous iron infusions because the disease onset was 3 weeks after the infusions and the changes were localized to the proximal forearm, the site of all of the infusions.
Our patient had anemia due to heavy uterine bleeding that predated the eosinophilic fasciitis and resolved with the intravenous iron infusions.
A 43-year-old African-American female with anemia secondary to uterine leiomyomas and menorrhagia presented with induration and stiffness of the right arm and hand four weeks after receiving intravenous iron infusions at multiple infusion sites along the right proximal forearm.
Because of the location of the fibrosis and the time proximity in relation to her infusions, a relationship between the iron infusions and eosinophilic fasciitis was made.
Eosinophilic fasciitis secondary to intravenous iron infusions.
It is not unlikely that intravenous iron may also be associated with eosinophilic fasciitis.
We feel it is important to describe this to increase awareness regarding a potential relationship between intravenous iron and eosinophilic fasciitis.

A majority of the Vegans/Vegetarian that I know have good health and even the herbalist that I worked for a few years ago said that I chose this diet because I cannot process meat in my body.
There was an info sheet but I am not sure if I am under during this procedure? Am I able to do things during the 3 hours I am being infused? Like listen to an or use my laptop or read? Any other info would be useful as so far I do’t know of anyone that has had this done.
You will find that different doctors believe different things but that stupid belief that meat is going to solve things is antiquated and not based on science.
I understand your point of view very well, but because of my intestinal problems,–I am simply not able to eat roughage,–I truly suffer for it and because of my intestinal strictures, things don’t pass the way they normally should.
The problem is meat rots in the gut and doesn’t break down very fast unlike a plant diet which passes through the body very fast.

It was finally decided that I either had an absorption issue or I was unable to hold the iron and I needed to see a hematologist and consider IV iron infusions.
It was finally decided that I either had an absorption issue or I was unable to hold the iron and I needed to see a hematologist and consider IV iron infusions.
But thankfully my hematologist has now ordered IV iron infusions! I start next week Friday.
I had labs drawn on Monday and I see my hematologist tomorrow to see if the ablation did anything and my 3 times daily iron helped bring my ferritin level of 5 up.
I was diagnosed with iron deficency anemia (my ferritin was at a 5) in August.
I was diagnosed with iron deficency anemia (my ferritin was at a 5) in August.
I just finished with 12 wks of Iv Iron Infusions..and have my apt with Hematologist tomorrow morning to see how many more I need.
Was it just your ferritin that was low? My H&H is fine, my iron is low but not drastically low..but low enough that I am on iron.
Was it just your ferritin that was low? My H&H is fine, my iron is low but not drastically low..but low enough that I am on iron.
I have been working very hard with a nutritionist to get my levels up through iron rich foods and iron supplements to no avail.
I did really well the day of the infusion, but the next day I was experiencing severe pain in my kidney area on my right side.
I have been working very hard with a nutritionist to get my levels up through iron rich foods and iron supplements to no avail.
I did really well the day of the infusion, but the next day I was experiencing severe pain in my kidney area on my right side.
My ferritin was <3, iron 6 and I’ve also got Thalasemia which cannot be fixed.. Have you guys checked for Thalasemia? .
I think that is why they felt I wasn’t able to absorb or hold my iron – hence the infusions.

The CMC-Infusion Center at Abbey Place is the perfect environment for individuals who are trying to juggle their work or family schedule with their personal needs.  The Infusion Center is centrally located, three miles away from the hospital’s main campus, making it easier for patients to navigate.

Bentley-Armadale Medicare Local has established a community based Iron Infusion clinic as a response to a lack of intravenous service delivery within the community. Iron deficiency has been identified as a major health issue affecting all age groups.

Redken and Rowenta have combined their technology and expertise to develop Steam Infusion, a breakthrough steam straightening iron that releases a continuous flow of steam which delivers conditioning treatments into the hair- the result hair that’s incredibly shiny, with natural fluid movement.